Merrimack Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring
November 10, 2016 11:44 AM ESTBTIG affirms Merrimack Pharma (Nasdaq: MACK) at Neutral following Q3 results and announced restructuring.
Analyst Ling Wang commented, Q16 ONIVYDE net revenues of $14.5M slightly missed consensus ($16.6M) and our estimate ($16.7M). It ended 3Q16 with cash & equivalents of $48.5M. Management provided updated... More
